Literature DB >> 19846281

The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study.

Harry Vilkman1, Jaana Kajander, Sargo Aalto, Tero Vahlberg, Kjell Någren, Topias Allonen, Erkka Syvälahti, Jarmo Hietala.   

Abstract

Lorazepam is a widely used anxiolytic drug of the benzodiazepine class. The clinical actions of benzodiazepines are thought to be mediated via specific allosteric benzodiazepine binding sites and enhancement of GABAergic neurotransmission in the brain. However, the indirect effects of benzodiazepines on other neurotransmitter systems have not been extensively studied. Previous experimental evidence suggests that benzodiazepines inhibit striatal dopamine release by enhancing the GABAergic inhibitory effect on dopamine neurons whereas very little is known about cortical or thalamic gamma-amino-butyric (GABA)-dopamine interactions during benzodiazepine administration. We explored the effects of lorazepam (a single 2.5 mg dose) on cortical and thalamic D(2/3) receptor binding using Positron-Emission Tomography (PET) and the high-affinity D(2/3)-receptor ligand [(11)C]FLB 457 in 12 healthy male volunteers. We used a randomized, double-blind and placebo-controlled study design. Dopamine D(2)/D(3) receptor binding potential was measured with the reference tissue method in several extrastriatal D(2)-receptor areas including frontal, parietal, temporal cortices and thalamus. The main subjective effect of lorazepam was sedation. Lorazepam induced a statistically significant decrease of D(2)/D(3) receptor BP(ND) in medial temporal and dorsolateral prefrontal cortex (DLPFC) that was also confirmed by a voxel-level analysis. The sedative effect of lorazepam was associated with a decrease in D(2)/D(3) receptor BP(ND) in the DLPFC. In conclusion, lorazepam decreased [(11)C]FLB 457 binding in frontal and temporal cortex, suggesting that cortical GABA-dopamine interaction may be involved in the central actions of lorazepam in healthy volunteers. The correlation between lorazepam-induced sedation and D(2)/D(3) receptor binding potential (BP) change further supports this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846281     DOI: 10.1016/j.pscychresns.2009.04.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

1.  Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis.

Authors:  Pontus Plavén-Sigray; Pauliina Ikonen Victorsson; Alexander Santillo; Granville J Matheson; Maria Lee; Karin Collste; Helena Fatouros-Bergman; Carl M Sellgren; Sophie Erhardt; Ingrid Agartz; Christer Halldin; Lars Farde; Simon Cervenka
Journal:  Mol Psychiatry       Date:  2021-11-10       Impact factor: 13.437

2.  The relationship between the dopaminergic system and depressive symptoms in cervical dystonia.

Authors:  E Zoons; M A J Tijssen; Y E M Dreissen; J D Speelman; M Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-17       Impact factor: 9.236

3.  On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study.

Authors:  Ana Weidenauer; Martin Bauer; Ulrich Sauerzopf; Lucie Bartova; Lukas Nics; Sarah Pfaff; Cecile Philippe; Neydher Berroterán-Infante; Verena Pichler; Bernhard M Meyer; Ulrich Rabl; Patrick Sezen; Paul Cumming; Thomas Stimpfl; Harald H Sitte; Rupert Lanzenberger; Nilufar Mossaheb; Alexander Zimprich; Pablo Rusjan; Georg Dorffner; Markus Mitterhauser; Marcus Hacker; Lukas Pezawas; Siegfried Kasper; Wolfgang Wadsak; Nicole Praschak-Rieder; Matthäus Willeit
Journal:  Transl Psychiatry       Date:  2020-01-08       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.